Longo, J., Smirnov, P., Li, Z., Branchard, E., van Leeuwen, J. E., Licht, J. D., . . . Penn, L. Z. (2020). The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia.
Chicago Style CitationLongo, Joseph, et al. "The Mevalonate Pathway Is an Actionable Vulnerability of T(4;14)-positive Multiple Myeloma." Leukemia 2020.
MLA CitationLongo, Joseph, et al. "The Mevalonate Pathway Is an Actionable Vulnerability of T(4;14)-positive Multiple Myeloma." Leukemia 2020.
Warning: These citations may not always be 100% accurate.